H ypoxic pulmonary hypertension (HPH) is a common type of pulmonary arterial hypertension. According to the updated clinical classification of pulmonary hypertension in the Fifth World Symposium on pulmonary hypertension, HPH belongs to Group 3 pulmonary hypertension owing to lung diseases and hypoxia.
H ypoxic pulmonary hypertension (HPH) is a common type of pulmonary arterial hypertension. According to the updated clinical classification of pulmonary hypertension in the Fifth World Symposium on pulmonary hypertension, HPH belongs to Group 3 pulmonary hypertension owing to lung diseases and hypoxia. 1 HPH associated lung or heart disease is a severe progressive vascular remodeling disease with high rates of morbidity and mortality. 2 Sustained hypoxia caused by disorders of the respiratory system, such as chronic obstructive pulmonary disease, obstructive sleep apnea, and chronic mountain sickness, results in the development of pulmonary vascular remodeling and increased pulmonary vascular resistance. 3, 4 The increased pulmonary vascular resistance leads to an elevated pulmonary arterial pressure and ultimately causes right ventricular (RV) failure and premature death. [5] [6] [7] Currently, no therapies can effectively reverse this disease or significantly prolong survival of patients. 2, 8 Hypoxia-induced excessive proliferation, apoptosis resistance, and migration of pulmonary artery smooth muscle cells (PASMCs) are the primary cellular bases of vascular remodeling in the development of HPH. 7 Endothelial injury caused by hypoxia exhibits dysregulation in endothelial cells influencing vascular remodeling and vasoconstriction. However, the exact molecular mechanism underlying the process of hypoxia-induced dysfunction in the disease is rarely known. Therefore, better understanding of the mechanisms and novel effective treatments for HPH are urgently needed.
The aquaporins (AQPs), a family of small water-transporting membrane proteins, are specifically expressed in cells of various organs that are associated with a wide range of physiological functions and human diseases, such as cancers, brain edema, epilepsy, and cardiovascular disease.
9 Aquaporin1 (AQP1) overexpressed is involved in cell proliferation, migration, and angiogenesis. [10] [11] [12] In lung, AQP1 is expressed in alveolar type II cells, microvascular endothelia and medial layer, and is modulated by hypoxia. 13 Our previous study demonstrated that AQP1 contributes to myocardial infarction in mice. 14 Additionally, previous research showed that Aqp1 deletion alters ventricular blood ejection and reduces oxygen consumption in mice. 15 However, no direct evidence for a physiological role of AQP1 in the pathogenesis of HPH has been determined to date. The primary objective of this study is to investigate the roles of AQP1 in the pathogenesis of HPH by using AQP1 knockout mice and to explore its possible mechanisms.
Materials and Methods
The authors declare that all supporting data are available within the article and in the online-only Data Supplement.
Animals and Experimental Design
Aqp1-null mice under CD1 genetic background were generated by targeted gene disruption as described previously. 16, 17 HPH animal model was established as previously described. 18 Twenty-eight male adult wild-type (WT) mice (12 weeks) and 28 male adult Aqp1-null mice (12 weeks) were used. The mice were kept in a specific pathogen-free grade animal facility with a 12-hour light-dark cycle. More mice were used in the in vitro study, and the relative limitation of sample numbers had a consistent impact on the overall research. All the experimental procedures followed the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines pertaining to animal experimentation and were approved by the Committee on Animal Research of Dalian Medical University, China. HPH animal model was established as previously described and simplified below. The mice were randomly divided into 4 groups (7 mice per group): (1) WT normoxia group; (2) Aqp1-null normoxia group; (3) WT hypoxia group; and (4) Aqp1-null hypoxia group. For normoxia groups, the mice were housed in room air with normobaric normoxia (21% O 2 ), and for chronic hypoxia groups, the mice were exposed to normobaric hypoxia (10% O 2 ) for 4 weeks.
SU5416-hypoxia (Su-Hyoxia) animal model of HPH was produced as previously reported approach 19 by using SU5416 treatment and hypoxia exposure for 3 weeks (7 mice per group). The SU5416 was suspended in a mixture of 0.5% carboxymethylcellulose sodium, 0.9% sodium chloride, 0.4% polysorbate 80, and 0.9% benzyl alcohol in deionized water (all from Solarbio). Animals in Su-hypoxia groups were injected subcutaneously with SU5416 at 20 mg/kg per week for 3 weeks and were exposed to normobaric hypoxia (10% O 2 ). The normoxic mice were injected with the same volume of vehicle alone.
Echocardiography
Transthoracic echocardiography was performed by Vevo 770 system VisualSonics (Toronto, Ontario, Canada) as previously described. 20, 21 At the end of our experiment, animals were anesthetized with isoflurane (3%) and then underwent M-mode echocardiography from a 30 MHz probe. The left ventricular (LV) internal dimension at diastole and systole, LV posterior wall thickness at diastole and systole, LV ejection fraction (%), and LV fractional shortening (%) were calculated.
Hemodynamic Experiments and Measurements of RV Hypertrophy
After 4-week hypoxia exposure, the mice were anesthetized with 2.4% tribromoethanol (15 mL/kg, intraperitoneal). A homemade polyethylene catheter, prefilled with heparin and linked to the pressure transducers, was inserted through the right jugular vein into the right ventricle, and the right ventricle systolic pressure (RVSP) was recorded by Power Lab Software (ADI Instruments). Next, the thorax was opened, and the lungs were perfused free of blood with saline. Then, the lungs and heart were removed to culture plate with cold, normal saline, and the lung tissues with blood were abandoned. The heart was dissected out, divided into RV, LV, and septum, and the different parts were weighted, respectively. The weight ratio of RV to LV plus septum was calculated as indices to reflect RV hypertrophy. The left lungs were stored in liquid nitrogen for subsequent experiments.
Morphological Investigation
The sagittal sections of right lungs were fixed in 4% paraformaldehyde solution for 72 hours and processed for paraffin embedding. The 4-μm-thick sections were cut, and the lung histology was examined through hematoxylin and eosin staining, along with elastic Van Gieson as stated in our previous description. 22 Morphological changes of the small pulmonary arteries were characterized by microscopic evaluation. Five pulmonary arteries (external diameters of 25-100μm) were randomly chosen from each mouse and analyzed with Image-Pro Plus, Version 6.0 (Media Cybernetics). The percent of medial wall area (WA%) was calculated to evaluate pulmonary vascular structure remodeling. WA%=(medial WA)/ (total vessel area)×100.
Immunofluorescent/Immunohistochemical Staining
For immunohistochemistry examination, the lung sections were stained with anti-α-SMA (smooth muscle actin) antibody and CD31 as we reported previously. 18 For double immunofluorescence staining, the lung sections were incubated with a primary anti-α-SMA mouse antibody and a primary anti-AQP1 rabbit antibody and were detected with secondary antibodies, Alexa 488 anti-rabbit and Alexa 568 antimouse. DAPI (4,6-diamidino-2-phenylindole) was used to label nuclei. Images were obtained with an Olympus fluorescence microscope.
The pulmonary vascular structure remodeling was further evaluated by integrated optical density (OD) of α-SMA immunohistochemistry and degree of muscularization in pulmonary arteries (external diameter of 25-100 µm).
The α-SMA is a marker of smooth muscle cells, and α-SMA staining positive parts represent the medial layer. Therefore, the quantitative immunohistochemical assessments were performed to present pulmonary arterial remodeling. The integrated OD was analyzed in the wall of the pulmonary arterioles.
The degree of pulmonary arteries muscularization was determined by α-SMA staining. Microscopic pictures were assessed in a blinded fashion. As previously described, 8 
Primary PASMCs Culture and Cell Treatments
Primary PASMCs were cultured as previously reported 18 and described simply below. The lungs of 3 individual male WT mice or Aqp1-null mice were obtained. Then, the pulmonary arteries were isolated under anatomic microscope, and the second to third branches of the intrapulmonary artery were dissected in sterile PBS. The pulmonary arterial tissues were digested by 0.2% collagenase type II dissolved with 0.1% BSA (bovine serum albumin) and incubated for 40 to 50 minutes at 37°C. Then, the cells were cultured in complete DMEM supplemented with 15% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL). The PASMCs were identified through immunohistochemical staining for α-SMA at microscopy. Cells between passages 3 and 6 were used for further experiments. Before each experiment, the cells were incubated in serum-free low-glucose DMEM for 12 hours. For experiments, cells were exposed to 21% or 1% O 2 . At least 3× were repeated, respectively.
Isolation and Culture of Mouse Lung Endothelial Cells
Primary mouse lung endothelial cells (MLECs) were isolated based on the method previously described. 24 Briefly, the lungs of 3 male WT mice or Aqp1-null mice (3 weeks) were obtained and incubated with collagenase I (Solarbio, 1 mg/mL) for 2 hours at 37°C. The digested material was filtered through sterile 70-μm nylon mesh and washed in 0.1% BSA/PBS. Subsequently, the cells were incubated with dynabeads (Invitrogen), which were prepared as follows: beads coated with sheep anti-rat IgG were incubated with purified rat anti-mouse CD31 monoclonal antibody (1 μg/ mL) at 4°C overnight and then washed with PBS containing 0.1% BSA. The cell suspension was incubated with beads for 1 hour at 4°C and then beads attached to MLECs were captured by a dynal magnet (Invitrogen). Finally, the beads attached to MLECs were cultured in ECM (endothelial cell medium; ScienCell) supplemented with 10% FBS, ECGS (endothelial cell growth supplement), penicillin (100 U/ mL), and streptomycin (100 μg/mL). For each experiment, cells were exposed to 21% or 1% O 2 , At least 3× were repeated, respectively.
Western Blot Analysis
Lung tissues, free of blood, were homogenized and lysed with ultrasonic cell disruptor. PASMCs, MLECs, and lung homogenates were lysed with ice-cold RIPA (radio immunoprecipitation assay) lysis buffer containing PMSF (phenylmethanesulfonyl fluoride; 1 mmol/L) for 30 minutes. Then the lysates were centrifuged with 12 000 rpm for 20 minutes, respectively, at 4°C, and the supernatant was collected. The concentrations of protein were determined by a Pierce BCA (bicincjoninic acid) protein assay kit. Equal amounts of proteins (25 μg for PASMCs protein and 40 μg for tissues protein) were separated with 10% SDS-PAGE, and then transferred to a nitrocellulose membrane, and blocked with 5% milk. The specific primary antibodies were rabbit antibodies against AQP1, caspase 3, caspase 9, P27, cyclin D, β-catenin, and β-actin. The signals were detected using ECL (enhanced chemiluminescent) kit. The OD of Western Blot was calculated with the Image lab software (Bio-Rad Laboratories, Hercules, CA).
Analysis of Cell Cycle
After hypoxia treatment for 24 hours, WT and Aqp1 deficient PASMCs were dissociated by trypsin, washed twice with PBS, and fixed with cold 75% ethanol at 4°C overnight. Cells were then collected, stained with 50 μg/mL propidium iodide (PBS 480 μL+5 μL propidium iodide [5 mg/Ml]+5 μL RNase [10 mg/mL]+10 μL Triton-100 [10%]) at 37°C for 30 minutes and kept in the dark. After centrifugation, the cells were suspended in PBS and detected for cell cycle. Cell cycle analysis was performed using a FACS Calibur Flow Cytometer (BD Biosciences, San Jose, CA). Further analyses were processed by Flow Jo software.
Wound Healing Assay
The WT and Aqp1 deficient PASMCs were cultured in 6-well plates for 24 hours to 60% to 80% confluence, and monolayer was scratched by a sterile pipette, which captured the images at the beginning. Then, the cells were exposed to hypoxia (1% O 2 ), and the images were captured after 24 hours. The images were compared to quantify the migration rate of the cells.
EdU Incorporation Assay and Hoechst 33342 Staining
Cell proliferation and apoptosis were detected by using kFluor488 Click-iT EdU (5-ethynyl-2'-deoxyuridine) Imaging Kit (KGA331-500, KeyGEN BioTECH) according to the producer's instructions. PASMCs and MLECs were planted onto 24-well plates. After hypoxia treatment for 24 hours, the cells were incubated with EdU at a final concentration of 50 µM for 2 hours. For Hoechst 33342 staining, cells were washed with PBS for 3× and then stained with a final concentration of 5 μg/mL Hoechst 33342 and incubated in dark at room temperature for 15 minutes. Hoechst 33342 stained cells were imaged under a fluorescent microscope with 350 nm excitation and 461 nm emission, and EdU stained cells were imaged under a fluorescent microscope with 495 nm excitation and 520 nm emission. At least 500 cells in each experiment were counted, and positive cells were expressed as a percentage of the total cells.
CCK8 Assay
Cell proliferation was measured with the cell counting kit-8 assay (CCK8, Abbkine, China) to assess the cell viability of PASMCs and MLECs under normoxia and hypoxia. Hundred microliters of cell suspension (5000 cells per well) was dispensed in a 96-well plate and were exposed to 21% or 1% O 2 . After the cells were cultured for 12, 24, and 48 hours, 10 μL CCK8 solution was added to each well of the plate. Then, the cells were incubated for 4 hours in incubator. Finally, the OD values were detected at 450 nm wavelength by a spectrophotometer.
Statistical Analyses
Results are expressed as means±SEM. At least 3 independent experiments (ran in duplicates) were performed for all in vitro studies. Statistical analyses were performed with SPSS software (version 20.0; SPSS, Inc, Chicago, IL), and graphs were generated using GraphPad Prism 5 (La Jolla, CA). Differences were considered statistically significant at a P value. The Kolmogorov-Smirnov test was applied to confirm the normality of distribution. All data passed normality of distribution. For 2-group comparisons, our data passed normality and equal variance tests, and Student t test was performed, with P<0.05 defined as statistically significant. For >2-group comparisons, if data passed normality and equal variance tests, 1-way ANOVA with a Tukey post hoc test at P<0.05 was used. Otherwise, if data passed normality but could not pass equal variance tests, Dunnett T3 test was performed, and statistical significance was accepted at P<0.05. Statistical results were specified in the figure legends.
Results

AQP1 Expression Was Upregulated by Chronic Hypoxia Exposure in Lungs and Pulmonary Arteries
To examine the role of AQP1 in the development of HPH, the AQP1 expression in lungs of was assessed by Western blot. Immunofluorescence was performed to further assess the expression of AQP1 in pulmonary arteries under chronic hypoxia. Compared with the normoxic group, chronic hypoxia exposure upregulated the expression of AQP1 in lung of WT mice ( Figure 1A and 1B). AQP1-positive cells were detected in pulmonary arteries of WT mice lung sections. Of note, AQP1 expression was upregulated by chronic hypoxia exposure not only in pulmonary arterial endothelial cells, but also in PASMCs of medial layer ( Figure 1C ).
AQP1 Deletion ASttenuated HPH
To detect the effects of Aqp1 deficiency on HPH, RVSP was recorded, and the weight ratio of RV to LV plus septum was calculated after exposure to hypoxia for 4 weeks. As shown in Figure 2A , WT mice of the hypoxia group exhibited significantly increased RVSP (33.18 mm Hg) in comparison to WT mice kept under normoxia condition (22.34 mm Hg). However, the RVSP of Aqp1-null mice in the hypoxia group was much lower than in WT mice of the hypoxia group. In accordance with the RVSP, the weight ratio of RV to LV plus septum was higher in WT mice exposed to hypoxic conditions compared with the WT mice in the normoxic control group, whereas the Aqp1-null mice under hypoxic conditions exhibited lower weight ratio of RV to LV plus septum ( Figure 2B ). Furthermore, we used the Su-hypoxic model, which better mimics pulmonary hypertension in humans. As with the previous model, Aqp1 deficiency attenuated the elevation of RVSP, Fulton index (RV/ LV+septum), and RV/BW (RV/body weight) but had few effects on heart rate in the Su-hypoxic model (Figure 3) . Additionally, Aqp1 deficiency produced no effect on left ventricular hemodynamics function ( Figure I in the onlineonly Data Supplement). Chronic hypoxia exposure upregulates AQP1 (aquaporin-1) expression in lungs and pulmonary arteries of mice. A, Western blot analysis of AQP1 expression in lung homogenate of wide-type (WT) mice and AQP1-null mice exposed to normoxia or hypoxia. β-actin was used as a loading control, respectively (n=3 individual samples per group). B, Bar graph shows the statistic results of AQP1 protein levels, respectively (1-way ANOVA with Tukey post hoc). C, Immunofluorescence staining for α-SMA (smooth muscle actin; in red), AQP1 (in green) in pulmonary arteries of WT mice, and AQP1-null mice under normoxia or hypoxia (n=3 each group). Values are means±SEM and *P<0.05. DAPI indicates 4,6-diamidino-2-phenylindole. January 2019
Aqp1 Disruption Reduced Chronic HypoxiaInduced Vascular Remodeling
We next investigated the role of AQP1 in hypoxia-induced pulmonary artery remodeling. The WA% of pulmonary arterioles, stained with HE, were calculated. As shown in Figure 4B , hypoxia markedly increased the WA% of WT mice, whereas the WA% of Aqp1-null mice under hypoxia was much lower. To determine the thickness and area of pulmonary arterioles which reflect the hyperplastic smooth muscularization in lungs, the integrated OD value of α-SMA immunohistochemical staining was calculated. As expected, α-SMA positive area of pulmonary arterioles was significantly increased in WT mice under chronic hypoxia compared with normoxia control mice, whereas this increment of the α-SMA positive area was lower in AQP-null mice of the hypoxia group ( Figure 4C ). The proportion of muscularized pulmonary arteries was also lower in AQP-null mice ( Figure 4D ). Furthermore, protruding endothelial cells detected by CD31 seen in WT mice pulmonary arterioles were also decreased in AQP-null mice ( Figure 4A ). As with the previous model, the Su-hypoxia pulmonary hypertension model showed the same results ( Figure 5 ). The α-SMA immunohistochemical staining of pulmonary arterioles represented pulmonary vascular lesions in normoxic, hypoxic, and Su-hypoxia-exposed mice lungs, acquired from occlusion by concentric neointimal proliferation. Occluded concentric lesion is a hallmark of plexiform lesions that is observed in Su-hypoxic-induced pulmonary hypertension in mice. To determine the impact of Aqp1 deficiency on pulmonary arteries muscularization, 3 groups shown in Figure 6 , including nonmuscularization, partial and full muscularization, were analyzed blindly in each mouse. We found that nonmuscularization vessels and partial muscularization vessels showed no significant change. Interestingly, full muscularization vessels showed conspicuous differences between the normoxia and hypoxia groups. Also, more remarkably, the percentage of lung full muscularization arterioles in Su-hypoxia WT animals was greater than those in the Su-hypoxia Aqp1 deficiency group.
Aqp1 Deletion Reversed HIF Overexpression Induced by Hypoxia and Repressed HIF-1α Protein Stability
HIFs (hypoxia-inducible factors) play essential roles in the development of HPH. [25] [26] [27] To learn whether Aqp1 deficiency could reverse the hypoxia-induced upregulation of HIF, expression of HIF-1α and HIF-2α in the lung were determined through Western blot analysis. Results showed that HIF-1α and HIF-2α expression in the whole lungs were upregulated under hypoxic conditions, whereas Aqp1 deficiency inhibited the upregulation of HIF-1α and HIF-2α ( Figure 7) . Furthermore, as shown in Figure 8 , by cycloheximide treatment, we found that Aqp1 deficiency repressed HIF-1α protein stability in PASMCs under hypoxia.
Aqp1 Deletion Reduced Hypoxia-Induced Proliferation, Promoted Apoptosis, and Arrested Cell Cycle of PASMCs
The imbalance of PASMCs proliferation and apoptosis is a crucial cellular mechanism accounting for hypoxiainduced pulmonary artery remodeling. To investigate the impact of AQP1 on PASMCs proliferation induced by hypoxia, the PASMCs from WT mice and Aqp1-null mice were cultured and identified. CCK8 assay showed that the viability of PASMCs from Aqp1-null mice was reduced compared with the cells from WT mice in normoxia and hypoxia conditions. Of note, the reduction was more significant under hypoxia ( Figure 9B) . Next, the expression of Ki67 was detected by immunofluorescence staining. Ki67 was upregulated by hypoxia, and Aqp1 deficiency attenuated the upregulation of Ki67 induced by hypoxia ( Figure 9C and 9D). Consistent with viability assay, PCNA (proliferating cell nuclear antigen) expression in PASMCs, detected by Western blot, exhibited similar results ( Figure 9E ). To gain more insight into cellular and molecular mechanisms underlying the observed PASMCs growth inhibition, we assessed the effect of AQP1 on the apoptosis of PASMCs. EdU staining and Hoechst 33342 staining were used to state that Aqp1 deletion reduced hypoxia-induced proliferation and promoted apoptosis of PASMCs ( Figure  10A-10C ). As expected, hypoxia downregulated the protein level of cleaved-caspase 9 and cleaved-caspase 3 in WT PASMCs, which means the normal apoptosis of PASMCs was suppressed. However, the expression of cleaved-caspase 9 and cleaved-caspase 3 were higher in Aqp1 deficient PASMCs under hypoxia compared with that of WT PASMCs ( Figure 10D-10F) .
We further determined whether the inhibition of cell growth caused by Aqp1 deficiency in PASMCs was associated with cell cycle arrest. After hypoxia treatment for 24 hours, the PASMCs were subjected to cell cycle analysis. We found that there is no significant difference between WT and Aqp1 deficient PASMCs exhibited under normoxia. However, higher percentage of Aqp1 deficient PASMCs was rested in G0/G1 phase of cell cycle (60.02%) compared with WT PASMCs exposed to hypoxia ( Figure 11A ).
Additionally, we determined the expression of 3 key proteins involved in cell cycle (cyclin D and P27) in PASMCs at 24 hours after hypoxia treatment. As shown in Figure 11B -11D, WT PASMCs hypoxia enhanced the expression of cyclin D and remarkably decreased that of P27. However, the upregulation of cyclin D and downregulation of P27 induced by hypoxia were significantly reversed by Aqp1 deficiency. To further prove the effects of AQP1 on cell cycle in PASMCs, after the WT and Aqp1 deficient PASMCs were treated with PDGF-BB (platelet-derived growth factor-BB) for 24 hours, we assessed cyclin D by Western blot. As shown in Figure II in the online-only Data Supplement, PDGF-BB treatment upregulated cyclin D, and Aqp1 deficiency significantly downregulated cyclin D.
Aqp1 Disruption Attenuated the Migration of PASMCs Induced by Hypoxia
Hypoxia-induced PASMCs migration is a key element of vascular remodeling during the development of HPH. We examined the role of AQP1 in hypoxia-induced migration and cytoskeleton reorganization of PASMCs using wound healing assay and Rhodamine-phalloidin staining for F-actin ( Figure 12A and 12C) . The results show that Aqp1 deficiency attenuated hypoxia-induced migration and reduced cytoskeleton reorganization of PASMCs ( Figure 12B ). To further explore the underlying mechanisms, β-catenin protein was detected by Western blot. As shown in Figure 12D , Aqp1 deletion reduced β-catenin protein level.
Aqp1 Deletion Protected Hypoxia-Induced Pulmonary Endothelial Injury
We did some concrete work on isolating pulmonary endothelial cell and exploring the roles of AQP1 on the cells under hypoxia. As Figure 13 shows, Aqp1 deficiency attenuated hypoxia-induced apoptosis of MLECs and protected endothelial cells from apoptosis in response to injury.
Discussion
By using HPH model, we found that the WT mice model exhibited higher pulmonary arterial pressure, right ventricle hypertrophy, and significant structural remodeling of small pulmonary vessels as in our previous reports. 18, 28 However, the pathological changes in Aqp1-null mice were partly reversed. Furthermore, Aqp1 deletion decreased the proliferative pathological changes in pulmonary arteries in mice. These results indicated that deficiency of aqp1 attenuates pulmonary artery pressure elevation and vascular remodeling in a chronic hypoxia mice model.
The pathogenesis of HPH involves a complex process in which dysfunction of PASMCs appear to play a crucial role in mediating the structural change of pulmonary vasculature. 29 Previous studies indicate that hypoxia exposure upregulates AQP1 expression and downregulates AQP5 expression in animal lungs, whereas other AQPs levels are not changed. 13, 30 We detected that chronic hypoxia exposure significantly caused AQP1 upregulation in both endothelial and medial layer of pulmonary arteries. It has been reported that the hypoxia-dependent upregulation of AQP1 directly depends on HIF-1α. 31 However, the activation of Aqp1 promoter induced by hypoxia is multifactorial. Aside from HIF-1α, other hypoxia-responsive transcription factors may contribute to this regulatory process, including NF-κB (nuclear factor κB), ETS1 (ETS pro-oncogene 1), and EGR1 (early growth response 1). 32 Additionally, hypoxia exposure increases [Ca 2+ ] i level, which is also important in upregulating AQP1 protein levels of PASMCs. 13 So, the hypoxia-dependent upregulation of AQP1 may be a multifactorial process in PASMCs. It has been known that HIF regulates vascular remodeling-related gene expression and contributes to pulmonary vascular remodeling and HPH pathogenesis. 25, 27, 33, 34 In this study, AQP1 deficiency reduced both HIF-1α and HIF-2α accumulation induced by hypoxia in lungs. And, in vitro, Aqp1 deficiency repressed HIF-1α protein stability under hypoxia. Previous study indicates that AQP1 is not only a water transporter but also an O 2 transporter in mammalian cells, and overexpression of AQP1 accelerates the loss of intracellular O 2 , leading to faster stabilization of HIF. 30 Another study demonstrates that Aqp1 knockdown represses HIF-2α protein stability in lung of mice, 35 suggesting a regulatory role of AQP1 in HIF accumulation. The detailed mechanism of the regulation between HIF and AQP1 needs to be further studied.
Consistent with previous study in which overexpression of AQP1 in cytoplasm promotes cell proliferation, 12 our current results indicate that hypoxia exposure also upregulates AQP1 expression in cytoplasm of PASMCs, and Aqp1 deficiency reduces the proliferation of PASMCs induced by hypoxia. In this study, deletion of Aqp1 reversed the downregulation of p27 induced by hypoxia in PASMCs. P27 is the primary negative regulator of CDK (cyclin-dependent kinase) in PASMCs, 36, 37 and p27 plays a critical role in the inhibition of hypoxia-induced PASMCs proliferation and vascular remodeling in HPH. 38, 39 Cyclin/CDK complexes are major regulators of the G1-phase progression in cell cycle. 36 D-cyclins are important components of the core cell cycle machinery. Overexpression of cyclin D is common in excessively proliferative cells, 40 and they play similar roles in cell cycle regulation. Previous reports have shown that Aqp1 plays important roles in cell cycle progression by regulating cyclin D and cyclin E. 41 In our study, Aqp1 deficiency remarkably reversed the hypoxia-induced upregulation of cyclin D in PASMCs and caused PASMCs cell cycle G0/G1 phase arrest under hypoxia condition. To further prove the effects of AQP1 on cyclin D, PASMCs were incubated with PDGF-BB, which has been known to induce PASMCs proliferation by accelerating cell cycle progress in the progression of PAH. 42, 43 Similar to hypoxia exposure, PDGF-BB treatment also upregulated the expression of cyclin D, and AQP1 deficiency significantly downregulated the level of cyclin D in PASMCs.
The balance between apoptosis and cell proliferation of PASMCs is important to maintain the normal structural and functional integrity of the pulmonary artery. Resistance of apoptosis, the common feature of PAH-PASMCs, 44 is a complex process in which multiple factors have been described to contribute to pulmonary vascular remodeling. 45 It has been known that hypoxia decreases PASMCs apoptosis through mitochondrial apoptotic or proliferative signaling pathway.
2 Hypoxia exposure reduces release of cytochrome c to the cytosol, resulting in suppressing PASMCs apoptosis. 46 Site-specific drugs enhancing apoptosis have successfully been used to reverse PH in animal models. 47, 48 In this study, Aqp1 deficiency upregulated the mitochondrial apoptotic proteins, cleaved-caspase 9 and cleaved-caspase 3, and reversed hypoxia-induced PASMCs apoptosis resistance. Thus, this data demonstrates that AQP1 could also affect the apoptosis resistance induced by hypoxia in PASMCs to contribute to vascular remodeling. PASMCs migration that occurs during the development of HPH is another crucial process of vascular remodeling. 13 Aqp1 upregulation has been suggested to play a role in hypoxiainduced PASMCs migration. 13, 49 We proved the impacts of AQP1 on PASMCs migration ability and regulation of actin cytoskeleton by Aqp1 deficient PASMCs. It has been demonstrated that AQP1 plays an important role in stabilizing cytoskeleton affecting migration capacity, and AQP1 affects the organization of the cytoskeleton through β-catenin.
50,51 AQP1 knockdown induced the proteolytic degradation of Lin7/β-catenin through proteasome complex. 52 In our study, Aqp1 deficiency downregulated β-catenin protein level, attenuated PASMCs migration, and reduced cytoskeleton reorganization under hypoxia condition. So, the effect of AQP1 on PASMCs migration may be another mechanism of HPH development.
In addition, endothelial dysfunction induced by hypoxia exhibits a multifaceted imbalance in endothelial cells production, influencing vascular remodeling and vasoconstriction. 5 Also, the abnormal proliferation and migration of pulmonary endothelial cell result in vessel luminal occlusion and plexiform lesions, which are present in up to 80% of the HPH patient population. [53] [54] [55] [56] It is known that AQP1 plays an important role in proliferation, migration, invasion, and angiogenesis of endothelial cells. 11, 57, 58 Endothelial cell apoptosis in response to injury is a transient, yet defining, pathogenic event that underlies many human vascular disorders, including pulmonary hypertension. [59] [60] [61] [62] We detected that AQP1 expression in pulmonary vascular endothelia was upregulated by hypoxia exposure, and AQP1 deficiency significantly reduced the protruding endothelial cells in pulmonary arteries. In vitro, AQP1 deletion protected endothelial cells from apoptosis in response to hypoxic injury. The data suggested that AQP1 may be related to MLECs dysregulation in HPH. AQP1 may also affect the phenotype of PASMCs through endothelial cell paracrine, but this research indicated that AQP1 deletion could directly and significantly affect the phenotype of PASMCs. Further study is necessary to demonstrate the role of AQP1 in MLECs dysregulation in HPH.
Pulmonary arterial remodeling caused by PASMCs dysfunction is responsible for increased pulmonary vascular resistance in all categories of pulmonary hypertension. 63, 64 Aqp1 deficiency attenuates hypoxia-induced abnormal proliferation, resistance of apoptosis, and migration ability of PASMCs. To date, the significance of AQP1 in pathogenesis of a wide range of human diseases, such as kidney diseases, hydrocephalus, glaucoma, 65 and cancers, has been reported. 66 The therapeutic inhibitor of AQP1 in cancer treatment has been proposed in reports. 66 At the current stage, our study suggests that AQP1 inhibitor could be a potential targeted therapeutic drug for PAH (pulmonary artery hypertension) treatment. Therefore, further development of specific and efficient AQP1 inhibitors is of great importance for clinical treatment. In summary, our report first revealed that AQP1 directly drives, at least in part, hypoxia-induced vascular remodeling, increased RV systemic pressure, as well as RV hypertrophy. This report is substantiated both by the partial protection of Aqp1 deficiency in mice from HPH and by the fact that hypoxia increases AQP1 expression in PASMCs and MLECs. Absence of AQP1 directly reverses hypoxia-induced dysregulation of PASMCs and MLECs.
In conclusion, our findings suggest that AQP1 promotes the development of HPH and that AQP1 may be a potential therapeutic target for PAH treatment. 
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